Why is precision medicine in cancer care important?

The standard of care for many cancer types frequently employs one-size-fits-all therapeutic strategies, which may involve multiple rounds of “best guess” treatment options. According to a survey from the Personalized Medicine Coalition[1], 75% of cancer patients do not benefit from the first drug offered; these patients must often endure the negative effects of therapies that may provide little clinical benefit. In addition, first-year cost of care can be upwards of $100,000 for many cancer types[2], which impacts medical expense for health insurance companies.

What is GPS Cancer™ ?

GPS Cancer is a unique, comprehensive molecular test available through NantHealth. GPS Cancer integrates whole genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and quantitative proteomics, providing oncologists with a comprehensive molecular profile of a patient’s cancer to inform personalized treatment strategies.

How does GPS Cancer help my providers and members?

By providing insight into the unique biology of the patient's tumor, GPS Cancer helps your network of oncologists to identify potential treatment options, including approved drugs and active clinical trials that correspond to the molecular composition of a patient’s individualized tumor.

What makes GPS Cancer different from other tests?

GPS Cancer is a unique molecular test that:

  • Includes whole genome sequencing of over 20,000 genes and 3 billion base pairs
  • Compares a patient’s tumor genome to their normal genome
  • Incorporates whole transcriptome sequencing of over 200,000 RNA transcripts
  • Leverages the power of quantitative proteomics

Cancer drugs often target proteins or require proteins to be effective. Specifically, through quantitative proteomics, knowing how much of each specific protein is present in a tumor can help oncologists to better understand which chemotherapies and targeted therapies may be effective.

Why should I consider coverage for GPS Cancer?

GPS Cancer is building strong market momentum. Today, leading health plans and employers seeing the value of a comprehensive molecular test that equips their providers with a detailed molecular profile of their patient’s cancer.

In January 2016, Independence Blue Cross became the first commercial payor to make GPS Cancer testing available to its members.

Independence Blue Cross is committed to bringing state-of-the-art advances in oncology to our members and making care accessible and affordable. Decisions around cancer care are complex and personal. We’re focused on supporting Independence members and their oncologists by offering coverage for this innovative approach to treating cancer. Whole genome sequencing is one more option to help inform a personalized, effective treatment plan.
— Daniel J. Hilferty - President and Chief Executive Officer of Independence Blue Cross

In May 2016, coverage for GPS Cancer further expanded, with Sanford Health Plan becoming the second commercial insurer to cover the test.

At Sanford Health, we are dedicated to offering our employees affordable and accessible high-quality care. Not only is GPS Cancer testing a novelty approach to cancer care, but it offers our employees – and their families – what we believe to be the best coverage for receiving improved cancer treatment options. As one of the founding members of the National Immunotherapy Coalition and Pediatrics Consortium, we are committed to the Cancer [Breakthroughs] 2020 program and its initiatives to win the war on cancer.
— Richard Adcock - Executive Vice President of Sanford Health

In addition to coverage by commercial health plans, Sanford Health and Phoenix Children’s Hospital have become the nation’s first self-insured employers to cover GPS Cancer for various cancers, helping their employees—and their families—to gain better insight and treatment strategies in optimizing cancer therapy.

Who should I contact for more information?

If you would like more information about GPS Cancer, please contact the GPS Care Center at 1-844-MY-OMICS/1-844-696-6427, or you can email us at GPSCancer@nanthealth.com.